Protagonist Therapeutics to Current on the forty first Annual J.P. Morgan Healthcare Convention
NEWARK, Calif., Dec. 21, 2022 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the
NEWARK, Calif., Dec. 21, 2022 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq: PTGX) (“Protagonist” or “the Firm”) immediately introduced that Dinesh V. Patel, Ph.D., President and Chief Govt Officer, will supply a company presentation and host one-on-one conferences with buyers on the 41st Annual J.P. Morgan Healthcare Convention, going down January 9-12 in San Francisco, California.
Presentation Particulars:
Date: Wednesday, January 11, 2023
Time: 7:30 a.m. PT
Location: Westin St. Francis, 335 Powell Road, San Francisco.
A webcast of the occasion will likely be out there on the Buyers part of the Protagonist Therapeutics web site at http://buyers.protagonist-inc.com/.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical firm with peptide-based new chemical entities rusfertide and PN-235 in superior levels of medical improvement, each derived from the Firm’s proprietary expertise platform. Rusfertide, a mimetic of the pure hormone hepcidin, is the Firm’s lead drug candidate at present in a worldwide Section 3 stage of improvement. The Section 3 VERIFY and Section 2 REVIVE research of rusfertide in polycythemia vera are ongoing. Protagonist retains all worldwide improvement and commercialization rights to rusfertide.
Protagonist has partnered with Janssen Biotech, Inc. on the event of oral IL-23 receptor antagonist PN-235 (JNJ-77242113) for all medical indications, together with psoriasis and inflammatory bowel illnesses. PN-235 is at present in a number of medical research together with a Section 2b research in moderate-to-severe plaque psoriasis, led by Janssen.
Protagonist is headquartered in Newark, California. For extra info on Protagonist, please go to the Firm’s web site at www.protagonist-inc.com.
SOURCE Protagonist Therapeutics, Inc.